ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 130 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,036,866 | -33.3% | 3,363,046 | +1.0% | 0.00% | 0.0% |
| Q2 2023 | $34,527,578 | +33.7% | 3,329,564 | +4.3% | 0.00% | 0.0% |
| Q1 2023 | $25,826,726 | -47.5% | 3,192,426 | +2.2% | 0.00% | 0.0% |
| Q4 2022 | $49,175,517 | +6.6% | 3,122,255 | +6.5% | 0.00% | 0.0% |
| Q3 2022 | $46,145,000 | +17.5% | 2,931,709 | +4.2% | 0.00% | 0.0% |
| Q2 2022 | $39,279,000 | -16.5% | 2,813,685 | +3.1% | 0.00% | 0.0% |
| Q1 2022 | $47,045,000 | +19.0% | 2,728,820 | +0.4% | 0.00% | 0.0% |
| Q4 2021 | $39,522,000 | -18.0% | 2,718,107 | +1.5% | 0.00% | 0.0% |
| Q3 2021 | $48,221,000 | +7.0% | 2,678,940 | +4.4% | 0.00% | 0.0% |
| Q2 2021 | $45,073,000 | -15.5% | 2,566,771 | +21.2% | 0.00% | 0.0% |
| Q1 2021 | $53,370,000 | +454.7% | 2,117,852 | +42.4% | 0.00% | – |
| Q4 2020 | $9,621,000 | +187.7% | 1,487,141 | +14.3% | 0.00% | – |
| Q3 2020 | $3,344,000 | +58.6% | 1,301,158 | 0.0% | 0.00% | – |
| Q2 2020 | $2,108,000 | +44.7% | 1,301,158 | -7.1% | 0.00% | – |
| Q1 2020 | $1,457,000 | -45.4% | 1,400,749 | -0.8% | 0.00% | – |
| Q4 2019 | $2,668,000 | +79.5% | 1,411,933 | +2.6% | 0.00% | – |
| Q3 2019 | $1,486,000 | -63.7% | 1,375,843 | -26.3% | 0.00% | – |
| Q2 2019 | $4,090,000 | -62.8% | 1,867,838 | +1.6% | 0.00% | – |
| Q1 2019 | $11,008,000 | +106.7% | 1,837,647 | +154.9% | 0.00% | – |
| Q4 2018 | $5,326,000 | -69.2% | 720,862 | -39.4% | 0.00% | -100.0% |
| Q3 2018 | $17,267,000 | -27.8% | 1,189,174 | -0.6% | 0.00% | 0.0% |
| Q2 2018 | $23,902,000 | +16.9% | 1,196,843 | +2.5% | 0.00% | 0.0% |
| Q1 2018 | $20,454,000 | -26.4% | 1,167,429 | +3.6% | 0.00% | 0.0% |
| Q4 2017 | $27,777,000 | -9.1% | 1,126,370 | -4.9% | 0.00% | 0.0% |
| Q3 2017 | $30,556,000 | +38.7% | 1,183,874 | +45.7% | 0.00% | 0.0% |
| Q2 2017 | $22,029,000 | +3.8% | 812,318 | +14.2% | 0.00% | 0.0% |
| Q1 2017 | $21,218,000 | +29.2% | 711,519 | +17.6% | 0.00% | 0.0% |
| Q4 2016 | $16,426,000 | +50.7% | 605,216 | +42.2% | 0.00% | 0.0% |
| Q3 2016 | $10,897,000 | +40.7% | 425,487 | +1.5% | 0.00% | – |
| Q2 2016 | $7,743,000 | +141.4% | 419,184 | +147.6% | 0.00% | – |
| Q1 2016 | $3,208,000 | -20.6% | 169,296 | +12.9% | 0.00% | – |
| Q4 2015 | $4,040,000 | – | 149,988 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |